ÂÜÀòÉç

Introduction

Drug toxicity remains one of the main causes of compound attrition in the drug development process. Compounds displaying organ, mechanism-based or off-target toxicity are just some of the safety issues that have contributed to drug development failures, and the need for robust early drug safety screening in an integrative manner is clear.This meeting will bring together a range of international experts from both industry and academia to present the new technologies and their applications in early drug safety assessment.

Useful links

Venue

National Heart and Lung Institute

Lecture Theatre, National Heart and Lung Institute, Dovehouse Street, Kensington, London, United Kingdom

Organised by

Society for Medicines Research

Contact information

Mr Stuart Hex
Q House, Troon Way Business Centre, Humberstone Lane, Thurmaston, Leicester, LE4 9HA, United Kingdom
0116 274 7356
Contact us by email

---